P III TRIAL OF DOXORUBICIN & CYCLOPHOSPHAMIDE FOL BY WEEKLY PACLITAXEL W/WO TRAS

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这是ECOG协议。本研究的目的是评估紫杉醇联合曲妥珠单抗作为肿瘤过表达HER-2的淋巴结阳性乳腺癌患者辅助治疗的一部分的排序。本研究将比较每3周辅助治疗阿霉素（ADR）和环磷酰胺（CTX）的疗效和毒性，随后是紫杉醇（TAXOL），每周单独给药12周，与曲妥珠单抗（HERCEP）与紫杉醇同时开始的方案。随后曲妥珠单抗治疗9个月，而曲妥珠单抗治疗在紫杉醇完成后开始并持续12个月

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is an ECOG protocol. The purpose of this study is to evaluate the sequencing of paclitaxel administration with trastuzumab as part of the adjuvant treatment of patients with node positive breast cancer whose tumors overexpress HER-2. This study will compare the efficacy and toxicity of adjuvant doxorubicin (ADR) and cyclophosphamide (CTX) every three weeks for four cycles followed by paclitaxel (TAXOL) administered weekly for twelve weeks alone versus this regime with trastuzumab (HERCEP) to be started concurrent with paclitaxel. Followed by trastuzumab for nine months versus this regime with trastuzumab started after the completion of Paclitaxel and continuing for twelve months